ClinicalTrials.gg
RecruitingNCT05563961Updated Mar 27, 2024

A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers

An interventional study of Panadol® and SafeTynadol® in Hepatitis and Pharmacology, sponsored by Sinew Pharma Inc.. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Sinew Pharma Inc. · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
20 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Hepatitis with a site in Taiwan — 3 open to participants now, 4 under way, none of them phase 3. Hepatitis · Taiwan.

Planned enrollment
19th of 21
48 · median 112
Started
2022
with 2 others
No phase
3 of 24
1 open now
Registered
21st of 24
by date
Lead sponsor
2 of 24
Sinew Pharma Inc.

Among the 24 studies in Hepatitis with a site in Taiwan, this one is the 19th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 with no phase, and was the 21st registered.

Hepatitis

344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.

Browse Hepatitis studies →

Open to participants now

3 of the 24 studies in Hepatitis with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 20 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hepatitis with a site in Taiwan, or all of them as a file.
02

Study summary

To investigate and compare the possible response of Panadol® and SafeTynadol® formulations in healthy volunteers and the safety in SafeTynadol® dose-limiting hepatotoxicity.

Read the detailed description

Subjects will be randomized to Cohort 1 and cohort 2 in the study without crossover, Cohort 3-8 will be a dose-escalation manner. An effort will be made to balance the number of males and females in each cohort.

The first treatment cohort 1 and 2 will enroll 12 study volunteers. The volunteers of cohort 1 will receive Panadol® oral dosage form is 500 mg*2 tablets = 1,000 mg/ person every 6 hours daily of the multiple-dose treatment (Q6H, total 4 dosages, 8 tablets, 4,000 mg) (n = 6) and cohort 2 will receive SafeTynadol® oral dosage form is 500 mg*2 tablets = 1,000 mg/ person every 6 hours daily of the multiple-dose treatment (Q6H, total 4 dosages, 8 tablets, 4,000 mg) (n = 6) in an single-blind, randomized manner.

About one to three weeks later, cohorts 3-8 will be studied in an order of increasing dose of SafeTynadol® starting from 4,500 mg increment to a maximum dose of 12,000 mg of SafeTynadol® if the previous cohort do not meet the significant criteria of hepatotoxicity.

Cohort 3-8 will initially enroll 3 study volunteers. Volunteers will receive SafeTynadol® oral dosage form is 500 mg*3 tablets at first dosage (1500 mg) and 500 mg every 6 hours *2 tablets at second to fourth dosage (1000 mg) person every 6 hours daily of the multiple-dose treatment (Q6H, total 4 dosages, 9 tablets, 4,500 mg) at cohort 3 or Volunteers will receive SafeTynadol® oral dosage form is 500 mg*3 tablets at first and second dosage (1500 mg) and 500 mg every 6 hours *2 tablets at third and fourth dosage (1000 mg) person every 6 hours daily of the multiple-dose treatment (Q6H, total 4 dosages, 10 tablets, 5,000 mg) at cohort 4 or Volunteers will receive SafeTynadol® oral dosage form is 500 mg*3 tablets = 1,500 mg/ person every 6 hours daily of the multiple-dose treatment (Q6H, total 4 dosages, 12 tablets, 6,000 mg) at cohort 5 or Volunteers will receive SafeTynadol® oral dosage form is 500 mg*4 tablets = 2,000 mg/ person every 6 hours daily of the multiple-dose treatment (Q6H, total 4 dosages, 16 tablets, 8,000 mg) at cohort 6 or Volunteers will receive multiple doses of SafeTynadol® oral dosage form 500 mg every 6 hours * 5 tablets = 2,500 mg/person every 6 hours daily of the multiple-dose treatment (Q6H, 4 doses, 20 tablets, 10,000 mg) at Cohort 7 or Volunteers will receive multiple doses of SafeTynadol® oral dosage form 500 mg every 6 hours * 6 tablets = 3,000 mg/person every 6 hours daily of the multiple-dose treatment (Q6H, 4 doses, 24 tablets, 12,000 mg) at Cohort 8.

In Cohort 3-8, liver function tests will be administered two hours after the third dose to confirm that the hepatotoxicity criteria are not met before the fourth dose can be administered and Cohort 6-8 will perform liver function tests two hours after the second dose administered to confirm that the hepatotoxicity criteria are not met before the third dose can be administered. After 3 study volunteers to confirm that did not meet significant hepatotoxicity occurs then another 3 study volunteers were included, study will in a dose-escalation manner.

Except at admission blood blank sampling to Clinical Research Center on day 1 at 10:00, sampling will be obtained at the following times last post dose: 0 (prior to the last dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours after administration (21 samples) to assess acetaminophen concentrations and its metabolites concentrations. In addition, Cohort 1-8 blood sample for liver function test (ALT, AST, total bilirubinl) and PT(INR) will be obtained on day 1 (10:00) after admission, two hours after the third dose on day 2 and 24, 48, 72, 96, 120 and 144 hours after the last dose, Cohort 6-8 will increase the assessment of liver function tests two hours after the second dose. Blood samples for blood chemistry, PT(INR), hematology (CBC) and OGSP will be collected on 168 hours for post-study evaluation.

03

Conditions studied

  • Hepatitis
  • Pharmacology

Keywords

  • acetaminophen
  • acute liver failure
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal healthy adult subjects between 20-50 years of age.
  • Body weight within 80-120% of ideal body weight.

    • Male Ideal body weight = (height - 80) x 0.7
    • Female Ideal body weight = (height - 70) x 0.6
  • Acceptable medical history and physical examination including:
  • normal results within six months prior to dosing.
  • no particular clinical significance in general disease history within two months prior to dosing.
  • Acceptable clinical laboratory determinations without significant deviation from normal values within two months prior to dosing, which includes (SGOT), ALT (SGPT), r-GT, alkaline phosphatase, total , albumin, glucose, BUN, uric acid, creatinine, total cholesterol, triglyceride (TG), PT() and OGSP.
  • Acceptable hematology within two months prior to dosing, which includes , hematocrit, red blood cells, MCV, MCH, MCHC, white blood cells, differential white blood cells and .
  • Acceptable urinalysis within two months prior to dosing, which includes pH, blood, glucose and protein.
  • Signed the written to participate in this study

Exclusion criteria

Exclusion Criteria:

  • History or presence of alcohol abuse, defined as consumption of more than 210 mL of alcohol per week (the equivalent of 14 glasses of 120-mL wine or 14 cans of 350-mL beer), or other substance abuse within the prior two years.
  • A disorder involving the allergy, cardiovascular, respiratory, renal, gastrointestinal/hepatic, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the clinical investigator).
  • History of allergic response(s) to acetaminophen, mannitol, sucralose or related drugs.
  • History of clinically significant allergies including drug allergies or allergic bronchial asthma.
  • Evidence of chronic or acute infectious diseases.
  • Any clinically significant illness or surgery during the two month prior to dosing (as determined by the clinical investigator).
  • Taking any drug known to induce or inhibit hepatic drug metabolism within one month prior to the beginning of the study.
  • Receiving any drug within one month prior to dosing.
  • Taking any prescription medication or any nonprescription medication within two weeks prior to dosing.
  • Donating greater than 150 ml of blood within two months prior to dosing or donating plasma (e.g. plasmapheresis) within two weeks prior to dosing.
  • Consumption of caffeine, xanthine-containing products (i.e. coffee, tea, caffeine-containing sodas, colas and chocolate, etc.) and/or alcohol within 48 hours prior to days on which dosing is scheduled and during the periods when blood samples are being collected.
  • Any other medical reason as determined by the clinical investigator.
  • Subject is pregnant or breastfeeding.
  • Women of disagree to use an acceptable method of (e.g., hormonal contraceptives, intrauterine device (IUD), barrier device or abstinence) throughout the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Panadol

    • Cohort 1- 6 Subjects to receive oral Panadol® 4,000 mg (2 tablets Q6H, 4 dosages, 8 tablets or 4,000 mg)

    Drug: Panadol®

  • Experimental
    SafeTynadol®

    * Cohort 2- 6 Subjects to receive oral SafeTynadol® 4,000 mg (2 tablets Q6H, 4 dosages, 8 tablets or 4,000 mg) * Cohort 3- 6 Subjects to receive oral SafeTynadol® 4,500 mg (3 tablets at first dosage and 2 tablets at second to forth dosage Q6H, 4 dosages, 9 tablets or 4,500 mg) * Cohort 4- 6 Subjects to receive oral SafeTynadol® 5,000 mg (3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H, 4 dosages, 10 tablets or 5,000 mg) * Cohort 5- 6 Subjects to receive oral SafeTynadol® 6,000 mg (3 tablets Q6H, 4 dosages, 12 tablets or 6,000 mg) * Cohort 6- 6 Subjects to receive oral SafeTynadol® 8,000 mg (4 tablets Q6H, 4 dosages, 16 tablets or 8,000 mg) * Cohort 7- 6 Subjects to receive oral SafeTynadol® 10,000 mg (5 tablets Q6H, 4 dosages, 20 tablets or 10,000 mg) * Cohort 8- 6 Subjects to receive oral SafeTynadol® 12,000 mg (6 tablets Q6H, 4 dosages, 24 tablets or 12,000 mg)

    Drug: SafeTynadol®

Interventions

  • DrugAcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)

  • DrugSafeTynadol®

    Test Drugs. Multiple-dose stage: Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)

06

What researchers measure

Primary outcomes

  1. ALT level within study periods

    Time frame: Day 1-9

Secondary outcomes

  1. Incidence of peak ALT elevations > 1X ULN within study periods

    Time frame: Day 1-9

  2. Incidence of peak ALT elevations > 2X ULN within study periods

    Time frame: Day 1-9

  3. Incidence of peak ALT elevations > 3X ULN within study periods

    Time frame: Day 1-9

  4. Incidence of peak ALT elevations > 5X ULN within study periods

    Time frame: Day 1-9

  5. Incidence of peak ALT elevations > 8X ULN within study periods

    Time frame: Day 1-9

  6. Incidence of total bilirubin > 2.5mg/dL within study periods

    Time frame: Day 1-9

  7. Incidence of PT (INR) > 1.25 within study periods

    Time frame: Day 1-9

  8. Hepatic failure rate

    Hepatic failure rate (hepatic encephalopathy, ascites, total bilirubin \>2.5mg/dL, PT(INR) \>1.25 , or liver transplantation) within study periods

    Time frame: Day 1-9

  9. Free plasma acetaminophen-cysteine (AAP-Cys) and AAP-Cys adducts

    The time-interval weighted area under the curve (AUC) of free plasma acetaminophen-cysteine (AAP-Cys) and AAP-Cys adducts within study periods

    Time frame: Day 1-9

  10. The time-interval weighted area under the curve (AUC) of ALT level within study periods

    Time frame: Day 1-9

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jun 2024, 20 months after the start.

Of 33 interventional studies with no phase under Hepatitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Oct 3, 2022
StartActual
Oct 28, 2022
Primary completionEst.
Jun 2024
CompletionEst.
Dec 2024
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05563961
Lead sponsor
Sinew Pharma Inc.
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Oct 28, 2022
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 27, 2024

Study contacts

ChengHuei Mr. Hsiong, Vice President
Contact
info@sinewpharma.com
+886-2-2788-5365
PoKuan Mr. Chao, Research
Contact
paikuan.chao@sinewpharma.com
+886-2-2788-5365

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion